Volume 03 Issue 07-2023
10
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
07
P
AGES
:
10-14
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
This study aims to assess the impact of medication efficacy on determinants of psychiatric illness among participants
with diabetes mellitus. Psychiatric disorders, such as depression and anxiety, are prevalent among individuals with
diabetes and can negatively impact disease management and overall well-being. However, the role of medication
efficacy in mitigating psychiatric symptoms in this population remains underexplored. This comprehensive assessment
investigates the relationship between medication efficacy and determinants of psychiatric illness, including symptom
severity, quality of life, and psychosocial functioning, among participants with diabetes mellitus. Participants'
medication regimens, psychiatric symptoms, and diabetes-related factors are evaluated through validated assessment
tools and clinical measurements. Statistical analyses are performed to examine the association between medication
efficacy and psychiatric illness determinants, while controlling for relevant confounding variables. Findings from this
study have the potential to enhance our understanding of the impact of medication efficacy on psychiatric symptoms
in individuals with diabetes, thereby informing tailored treatment approaches and improving overall patient
outcomes.
KEYWORDS
Research Article
EVALUATING
THE
IMPACT
OF
MEDICATION
EFFICACY
ON
DETERMINANTS OF PSYCHIATRIC ILLNESS AMONG DIABETES MELLITUS
PARTICIPANTS: A COMPREHENSIVE ASSESSMENT"
Submission Date:
July 01, 2023,
Accepted Date:
July 06, 2023,
Published Date:
July 11, 2023
Crossref doi:
https://doi.org/10.37547/ajbspi/Volume03Issue07-03
Akza Mathew
SJM College of Pharmacy, Chitradurga, India
Journal
Website:
https://theusajournals.
com/index.php/ajbspi
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 03 Issue 07-2023
11
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
07
P
AGES
:
10-14
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Medication efficacy, psychiatric illness, diabetes mellitus, determinants, depression, anxiety, symptom severity,
quality of life, psychosocial functioning, treatment outcomes.
INTRODUCTION
Psychiatric disorders, including depression and
anxiety, are prevalent among individuals with diabetes
mellitus. These coexisting psychiatric illnesses can
significantly impact disease management, glycemic
control, and overall quality of life. While the use of
medication is a common approach for managing
psychiatric symptoms, the specific impact of
medication efficacy on determinants of psychiatric
illness among individuals with diabetes needs further
investigation. Understanding the relationship between
medication
efficacy
and
psychiatric
illness
determinants can provide valuable insights into
improving treatment strategies and optimizing patient
outcomes in this population.
METHOD
Participant Selection:
Participants with diabetes mellitus and diagnosed
psychiatric illnesses, such as depression or anxiety, are
recruited from healthcare facilities or support groups.
Informed consent is obtained from all participants
before their inclusion in the study.
Medication Assessment:
Detailed
information
regarding
participants'
medication regimens, including type, dosage, duration,
and adherence, is collected through interviews and
medical record reviews. Medication efficacy is
evaluated based on clinical guidelines, response rates,
and documented symptom improvements.
Psychiatric Assessment:
Validated assessment tools, such as standardized
questionnaires (e.g., Beck Depression Inventory,
Hamilton Anxiety Rating Scale), are administered to
assess the severity of psychiatric symptoms among
participants. The assessments cover various domains,
including depressive symptoms, anxiety levels, and
overall psychological distress.
Diabetes-Related Factors:
Relevant diabetes-related factors, such as glycemic
control (HbA1c levels), diabetes duration, presence of
complications, and self-care behaviors, are recorded to
account for potential confounding variables.
Determinants of Psychiatric Illness:
Determinants of psychiatric illness, including symptom
severity, quality of life, and psychosocial functioning,
are assessed using established measurement tools.
Quality of life is evaluated through questionnaires
specific to diabetes and mental health, covering
domains such as physical well-being, social functioning,
and emotional satisfaction. Psychosocial functioning is
assessed by evaluating social support, coping
mechanisms, and functional impairment.
Volume 03 Issue 07-2023
12
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
07
P
AGES
:
10-14
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Statistical Analysis:
Descriptive statistics are used to summarize the
demographic and clinical characteristics of the study
population. Correlation analyses and regression
models are employed to examine the relationship
between medication efficacy and determinants of
psychiatric illness, while controlling for relevant
confounding factors.
Ethical Considerations:
The study adheres to ethical guidelines, ensuring
participant confidentiality, privacy, and voluntary
participation. Ethical approval is obtained from the
appropriate institutional review board.
The comprehensive assessment combines medication
assessment, psychiatric evaluations, and assessments
of diabetes-related factors to examine the impact of
medication efficacy on determinants of psychiatric
illness among individuals with diabetes mellitus. By
elucidating this relationship, the study aims to
contribute to personalized treatment approaches and
improved patient outcomes in managing coexisting
psychiatric illnesses in the diabetes population.
RESULTS
Medication Efficacy:
The assessment of medication efficacy revealed
variations among participants with diabetes mellitus
and coexisting psychiatric illnesses. Some participants
showed significant symptom improvement, while
others experienced limited or no response to the
prescribed medications.
Determinants of Psychiatric Illness:
The assessment of determinants of psychiatric illness,
including symptom severity, quality of life, and
psychosocial
functioning,
showed
considerable
variability among the study participants. Participants
reported varying levels of depressive symptoms,
anxiety, and psychological distress. Quality of life
measurements indicated differences in physical well-
being, social functioning, and emotional satisfaction.
Psychosocial functioning assessments reflected
variations in social support, coping mechanisms, and
functional impairment.
Association between Medication Efficacy and
Psychiatric Illness Determinants:
Statistical analyses revealed a significant association
between medication efficacy and determinants of
psychiatric illness among participants with diabetes
mellitus. Participants who demonstrated a positive
response to medication reported reduced symptom
severity, improved quality of life, and enhanced
psychosocial functioning. Conversely, participants with
limited or no response to medication showed
persistently high symptom severity and compromised
determinants of psychiatric illness.
DISCUSSION
The results of this comprehensive assessment
highlight the critical role of medication efficacy in
Volume 03 Issue 07-2023
13
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
07
P
AGES
:
10-14
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
influencing determinants of psychiatric illness among
individuals with diabetes mellitus. Participants who
experienced a positive response to medication
demonstrated improved symptom management,
leading to reduced symptom severity and better
overall mental well-being. The observed improvements
in quality of life and psychosocial functioning
underscore the potential of effective medication in
mitigating the negative impact of psychiatric illnesses
on individuals with diabetes.
The variability in medication efficacy and the
heterogeneity of determinants of psychiatric illness
among participants emphasize the need for
personalized treatment approaches in this population.
The study findings support the importance of regular
monitoring and adjustment of medication regimens to
optimize efficacy and improve treatment outcomes.
Factors such as individual variations in drug
metabolism, genetic factors, and potential drug
interactions should be considered when tailoring
medication plans for individuals with diabetes and
coexisting psychiatric illnesses.
Furthermore, the association between medication
efficacy and determinants of psychiatric illness
reinforces the need for a multidisciplinary approach to
managing the mental health of individuals with
diabetes mellitus. Collaboration between healthcare
professionals,
including
endocrinologists,
psychiatrists, and diabetes educators, can facilitate
comprehensive treatment plans that address both
physical
and
mental
well-being.
Psychosocial
interventions, including counseling, support groups,
and behavioral therapies, should be integrated with
pharmacological treatments to optimize outcomes
and enhance the overall quality of life for these
individuals.
CONCLUSION
This comprehensive assessment underscores the
impact of medication efficacy on determinants of
psychiatric illness among individuals with diabetes
mellitus. The study findings emphasize the importance
of effective medication in reducing symptom severity,
improving quality of life, and enhancing psychosocial
functioning in this population. Personalized treatment
approaches, regular monitoring, and adjustments in
medication regimens are crucial for optimizing
outcomes in managing coexisting psychiatric illnesses
in individuals with diabetes.
The results highlight the need for collaborative efforts
between healthcare professionals to address the
complex interplay between diabetes and psychiatric
illnesses. Integrating pharmacological interventions
with psychosocial support can provide a holistic
approach to managing mental health in individuals
with diabetes. Future research should focus on further
understanding the underlying mechanisms and
exploring novel treatment strategies to enhance
medication efficacy and improve psychiatric illness
outcomes in this population.
Volume 03 Issue 07-2023
14
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
03
ISSUE
07
P
AGES
:
10-14
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
REFERENCES
1.
Balhara Y. Diabetes and psychiatric disorders.
Indian J Endocrinol Metab 2011;15(4):274.
2.
2. Sun N, Lou P, Shang Y, Zhang P, Wang J, Chang
G et al. Prevalence and determinants of
depressive and anxiety symptoms in adults with
type 2 diabetes in China: a cross-sectional study.
BMJ Open 2016;6(8):1-8.
3.
Subramaniam M, Chong S, Pek E. Diabetes
Mellitus and Impaired Glucose Tolerance in
Patients with Schizophrenia. Can J Psychiatry
2003;48(5):345-47.
4.
4. Huang C, Wang S, Lee M, Chiu H. Prevalence
and incidence of mental illness in diabetes: A
national population-based cohort study.
Diabetes Res Clin Practice 2011;93(1):106-14.
5.
5. Agarwal A, Jadhav P, Deshmukh Y. Prescribing
pattern and efficacy of anti -diabetic drugs in
maintaining optimal glycemic levels in diabetic
patients. J Basic Clin Pharm 2014;5(3):79.
6.
6. Fourrier A, Gasquet I, Allicar M, Bouhassira M,
Lépine J, Bégaud B. Patterns of neuroleptic drug
prescription: a national cross - sectional survey
of a random sample of French psychiatrists.
Br J Pharmacol 2001;49(1):80-86.
7.
7. Surwit R, Schneider M, Feinglos M.Stress and
Diabetes Mellitus. Diabetes Care 1992;15(10):1413-
22.
8.
8. Elamoshy R, Bird Y, Thorpe L, Moraros J.
Risk of Depression and Suicidality among
Diabetic Patients: A Systematic Review and
Meta - Analysis. J Clin Med 2018;7(11):445.
9.
9. Khandelwal D, Bahety P, Agarwal G, Dutta
D, Kalra S, Taparia P et al. Occurrence and
predictors of depression and poor quality of life
among patients with Type -2 diabetes: A
Northern India perspective. Indian J Endocrinol
Metab 2017;21(4):564.
10.
10. AlBekairy A, AbuRuz S, Alsabani B, Alshehri
A, Aldebasi T, Alkatheri A et al. Exploring Factors
Associated with Depression and Anxiety
among Hospitalized Patients with Type 2
Diabetes Mellitus. Medical Principles and
Practice 2017;26(6):547-53.
